Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 2 institutions in 2 countries.
Krisztina S NagyLaboratory of Nanochemistry, Department of Biophysics and Radiation Biology, Semmelweis University, Nagyvárad tér 4, 1089 Budapest, Hungary.ORCID 0000-0002-4942-2947
Krisztina TothLaboratory of Nanochemistry, Department of Biophysics and Radiation Biology, Semmelweis University, Nagyvárad tér 4, 1089 Budapest, Hungary.ORCID 0000-0002-7939-5492
Eva PallingerDepartment of Genetics, Cell- and Immunobiology, Semmelweis University, Nagyvárad tér 4, 1089 Budapest, Hungary.
Angela TakacsDepartment of Genetics, Cell- and Immunobiology, Semmelweis University, Nagyvárad tér 4, 1089 Budapest, Hungary.
Laszlo KohidaiDepartment of Genetics, Cell- and Immunobiology, Semmelweis University, Nagyvárad tér 4, 1089 Budapest, Hungary.ORCID 0000-0002-9002-0296
Angela Jedlovszky-HajduLaboratory of Nanochemistry, Department of Biophysics and Radiation Biology, Semmelweis University, Nagyvárad tér 4, 1089 Budapest, Hungary.ORCID 0000-0003-2720-783X
Domokos MatheHungarian Center of Excellence for Molecular Medicine (HCEMM), In Vivo Imaging Advanced Core Facility, Semmelweis University Site, 1094 Budapest, Hungary.
Noemi KovacsDepartment of Biophysics and Radiation Biology, Semmelweis University, 1094 Budapest, Hungary.
Daniel S VeresDepartment of Biophysics and Radiation Biology, Semmelweis University, 1094 Budapest, Hungary.ORCID 0000-0002-9687-3556
Krisztian SzigetiDepartment of Biophysics and Radiation Biology, Semmelweis University, 1094 Budapest, Hungary.ORCID 0000-0002-0828-9828
Kristof MolnarDepartment of Food, Agricultural and Biological Engineering, College of Food, Agricultural, and Environmental Sciences, The Ohio State University, 222 FABE, 1680 Madison Avenue, Wooster, OH 44691, USA.ORCID 0000-0002-5393-2130
Eniko KrischDepartment of Food, Agricultural and Biological Engineering, College of Food, Agricultural, and Environmental Sciences, The Ohio State University, 222 FABE, 1680 Madison Avenue, Wooster, OH 44691, USA.
Judit E PuskasDepartment of Food, Agricultural and Biological Engineering, College of Food, Agricultural, and Environmental Sciences, The Ohio State University, 222 FABE, 1680 Madison Avenue, Wooster, OH 44691, USA.
Semmelweis University · HUThe Ohio State University · US
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
Breast Cancer Innovation Foundation NAEuropean Union's Horizon 2020 research and innovation program 739593HCEMM supported by EU Program H2020-EU.4.aHigher Education Institutional Excellence Program of the Ministry of Human Resources in Hun-gary, within the framework of the Therapeutic Development thematic program of Semmelweis University NAHungarian National Research, Development and Innovation Office (Thematic Excellence Program, TKP-BIOImaging) 2020-4.1.1-TKP2020János Bolyai Research Scholarship of the Hungarian Academy of Sciences JHANational Research, Development and Innovation Office of Hungary NKFIH FK 124147NCI NIH HHS P30 CA016058new national excellence program of the Ministry for Innovation and Technology ÚNKP-20-5-SE-9
6 · The paper itself
Abstract
This paper focuses on preliminary in vitro and in vivo testing of new bivalent folate-targeted PEGylated doxorubicin (DOX) made by modular chemo-enzymatic processes (FA
Indexed as
DoxorubicinFolic AcidNanoparticlesTriple Negative Breast NeoplasmsAnimalsCell Line, TumorFemaleFlow CytometryHumansMaleMiceMice, NudeXenograft Model Antitumor AssaysDoxorubicinFolic Acidchemo-enzymatic synthesisfolate-targeted cancer diagnosisin vitro screeningin vivo screeningmultivalencypolymer conjugates
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Folate-Targeted Monodisperse PEG-Based Conjugates Made by Chemo-Enzymatic Methods for Cancer Diagnosis and Treatment. · full record | OpenQuestion